General Comments / Chat, page-7215

So let's get down to the meat and potatoes.

The facts:

• ~$3.4B USD globally peak rev just for breast cancer.
• A (very conservative-sounding) USD $5-8bn peak revenue if additional indications are proven out and sold ex-US.
• Estimated $USD 15-20,000 per dose pricing and management.
• FTO not factored into this valuation. AML and other indications still coming.
• BOD are looking at an IP that could be sold either as cardoprotective in combo, or as a cardio and anti-cancer treatment (we already know Zantrene works against multiple cancer types and this is currently being proven out in clinic)

Calculating value is a fun exercise (I'll leave that to @LongTony). The figures are going to make a lot of people blush.

We are sub-$2.

I'll say that again.

We are sub-$2.

If the BOD can align a few interested parties and get them bidding, we are looking at a blockbuster. I believe this is happening now.

The video is great and 100% essential watching if you need a RAC pick-me-up or refresher on how huge this opportunity is: